利用全国症状监测数据估算英格兰婴儿接种B群脑膜炎球菌疫苗后发热的基层就诊率
2015年9月英国将4CMenB疫苗纳入国家婴儿免疫规划,早期临床试验显示51-61%的婴儿在同时接种其他常规疫苗后出现发热。本研究利用TPP ResearchOne全科医学数据库,比较疫苗引入后一年与之前两年疫苗适龄婴儿的全因发热咨询率,发现7-10周龄和15-18周龄婴儿的咨询率分别升高1.58倍和1.47倍,估计全英格兰额外增加1825次发热咨询。
要点
- 疫苗引入后7-10周龄婴儿全因发热咨询率升高1.58倍(IRR 1.58;95%CI 1.22-2.05)。
- 15-18周龄婴儿全因发热咨询率升高1.47倍(IRR 1.47;95%CI 1.17-1.86)。
- 0-6周龄和11-14周龄婴儿的全因发热咨询率无显著差异。
核心结论
- 在同时接种其他疫苗的4CMenB疫苗适龄婴儿中,全因发热咨询率出现小幅但显著的差异。
研究设计与样本
- 利用TPP ResearchOne全科医学数据库,通过Read(CTV3)编码识别疫苗引入后一年内婴儿全因发热咨询,计算日均咨询率和发病率比(IRR),并与疫苗引入前两年比较,估计疫苗引入前后全因发热咨询的差异。
主要发现
- 7-10周龄疫苗适龄婴儿的全因发热咨询率较前两年升高1.6倍(IRR 1.58;95%CI 1.22-2.05)。
- 15-18周龄疫苗适龄婴儿的全因发热咨询率较前两年升高1.5倍(IRR 1.47;95%CI 1.17-1.86)。
- 0-6周龄和11-14周龄婴儿的全因发热咨询率无显著差异。
- 将疫苗引入前后咨询率差异应用于全英格兰4CMenB疫苗适龄年龄组,估计疫苗引入后一年内额外增加1825次发热咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In September 2015, the United Kingdom became the first country to introduce the multicomponent group B meningococcal vaccine (4CMenB) into a national infant immunisation programme. In early clinical trials 51-61% of infants developed a fever when 4CMenB was administered with other routine vaccines. Whilst administration of prophylactic paracetamol is advised, up to 3% of parents may seek medical advice for fever following vaccination. We used research-level general practitioner consultations to identify any increase in attendances for all-cause fever in vaccine-eligible infants following 4CMenB introduction in England. METHODS: Consultations for infant all-cause fever in the year following the vaccine introduction were identified from The Phoenix Partnership (TPP) ResearchOne general practice database using Read (CTV3) codes. Average daily consultation rates and incidence rate ratios (IRRs) were calculated for vaccine-eligible age groups and compared to the two years preceding vaccine introduction. The difference between pre- and post-vaccine all-cause fever consultations was estimated. RESULTS: All-cause fever consultations in vaccine-eligible 7-10 week olds were 1.6-fold higher (IRR, 1.58; 95% CI, 1.22-2.05) compared to the two previous years and 1.5-fold higher (IRR 1.47; 95% CI, 1.17-1.86) in 15-18 week-olds. There were no significant differences in 0-6 or 11-14 week-olds. Applying the difference between pre- and post-vaccine consultation rates to the 4CMenB vaccine-eligible age groups across England estimated 1825 additional fever consultations in the year following 4CMenB introduction. CONCLUSIONS: We found a small but significant difference in all-cause fever consultation rates in vaccine-eligible infants who would have received 4CMenB with other vaccines.
引用
- Harcourt S, Morbey RA, Bates C, et al. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Vaccine. 2017. PMID: 29246475. doi:10.1016/j.vaccine.2017.11.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。